title: Conjunctival intraepithelial neoplasia. Interferon as a rescue therapy after failure of mitomycin C.
abstract: METHODS
  The case of a 60 year-old male with a conjunctival lesion diagnosed as conjunctival intraepithelial neoplasia (CIN), who was treated with mitomycin-C for 3 weeks with minimal improvement. The therapy was change to interferon 2B. Six month later, and after a complete remission of the lesion, the treatment was suspended, with no signs of relapse.
  
  
  CONCLUSIONS
  The treatment of these lesions is currently made with chemotherapy and immunotherapy agents, such as mitomycin-C, 5-fluorouracil, and interferon alfa 2B. The latter, even although is the least used, gives excellent results with fewer secondary effects than mitomycin-C, resulting in an optimal therapy for the non-invasive treatment of CIN lesions.
authors.affiliation: Servicio de Oftalmología, Hospital Clínico Universitario de Valencia, Valencia, España. Electronic address: delacruzaguilo@gmail.com.
authors.forename: R I
authors.initials: RI
authors.lastname: de la Cruz Aguiló
authors.affiliation: Servicio de Oftalmología, Hospital Clínico Universitario de Valencia, Valencia, España.
authors.forename: A
authors.initials: A
authors.lastname: Duch-Samper
authors.affiliation: Servicio de Oftalmología, Hospital Clínico Universitario de Valencia, Valencia, España.
authors.forename: D
authors.initials: D
authors.lastname: Hernández Pérez
authors.affiliation: Servicio de Oftalmología, Hospital Clínico Universitario de Valencia, Valencia, España.
authors.forename: J
authors.initials: J
authors.lastname: Marí Cotino
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy*; D003230:Conjunctival Neoplasms / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm; D057915:Drug Substitution; D006801:Humans; D006940:Hyperemia / Q000209:etiology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012074:Remission Induction; D016879:Salvage Therapy
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D016685:Mitomycin
keywords: 5-fluorouracil; 5-fluorouracilo; Conjunctival intraepithelial neoplasia; Immunotherapy; Inmunomoduladores; Interferon alfa 2B; Interferón alfa 2B; Mitomicina C; Mitomycin-C; Neoplasia intraepitelial corneal